Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
June 12, 2020 06:00 ET
|
Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
June 03, 2020 08:00 ET
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
May 18, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, May 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
May 15, 2020 07:30 ET
|
Aprea Therapeutics
BOSTON, May 15, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
April 06, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, April 06, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
February 13, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
January 30, 2020 07:30 ET
|
Aprea Therapeutics
BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
January 09, 2020 08:00 ET
|
Aprea Therapeutics
BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
December 12, 2019 08:30 ET
|
Aprea Therapeutics
BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented...